EPISODE · Nov 26, 2024 · 20 MIN
Resident Blog - Edith Ford
from The mTOR You Know · host The mTOR You Know
PGY2 SOT Edith Ford joins us from Mayo Clinic in Phoenix, Arizona to discuss "A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection", which has recently received Breakthrough Therapy Designation for ABMR in kidney transplant recipients, as well as a quick discussion on antibody-mediated rejection and CD38 inhibitors.
What this episode covers
PGY2 SOT Edith Ford joins us from Mayo Clinic in Phoenix, Arizona to discuss "A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection", which has recently received Breakthrough Therapy Designation for ABMR in kidney transplant recipients, as well as a quick discussion on antibody-mediated rejection and CD38 inhibitors.
NOW PLAYING
Resident Blog - Edith Ford
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m